Nivolumab Plus Relatlimab Induces Sturdy Responses in Complex Melanoma

The mix of nivolumab (nivolumab) and relatlimab (Opdualag) demonstrated medical receive advantages with a manageable protection profile in sufferers with complex melanoma who had stepped forward on earlier PD-L1 or PD-1 inhibitors, irrespective of PD-L1 and LAG expression. -3, in step with the result of the continued Section 1/2a RELATIVITY Experiment-020 (NCT01968109).1 At a medical … Read more